BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//financecalendar.com - ECPv6.17.4.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.financecalendar.com
X-WR-CALDESC:Events for financecalendar.com
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20280312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20281105T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20270202T050000
DTEND;TZID=America/New_York:20270202T060000
DTSTAMP:20261019T210243Z
CREATED:20261019T210243Z
LAST-MODIFIED:20261019T210243Z
UID:2958-1801544400-1801548000@www.financecalendar.com
SUMMARY:Eurozone Flash CPI February 2027
DESCRIPTION:Next Eurozone Flash CPI: Tuesday\, February 2\, 2027 at 11:00 am CET (5:00 am ET\, 10:00 am London). Covers January 2027 data. \nDate to be confirmed by the publisher; this is the scheduled date. \n\nConsensus\nNot yet published\nPrior\n2.8% (June 2026 flash\, most recent confirmed)\nActual\nPending\n\nFull schedule and background: Eurozone Flash CPI. \nUpdated October 19\, 2026 \n\n← Previous Eurozone Flash CPI\nThe Eurozone Flash CPI for February 2027\, covering January 2027 price data\, is scheduled for release on February 2\, 2027 at 5:00 am ET (10:00 am London\, 11:00 am CET). The figures are published by Eurostat\, the statistical office of the European Union\, as a preliminary “flash” reading of annual inflation across the 20 countries that use the euro. Full background and the release schedule for this series are on the Eurozone Flash CPI hub page. \nWhat is the Eurozone Flash CPI?\nThe Flash CPI (formally the flash estimate of the Harmonised Index of Consumer Prices\, or HICP) is Eurostat’s earliest snapshot of how much prices have risen across the euro area over the previous 12 months. It covers a broad basket of goods and services\, including food\, energy\, housing\, transport and services such as restaurants and insurance\, weighted to reflect typical household spending across member states. \nBecause it arrives before national statistical offices have finalised every input\, the flash figure is an estimate rather than a final number. It is usually close to the confirmed reading published around three weeks later\, but revisions do happen\, particularly in volatile categories such as energy and unprocessed food. \nMarkets watch this release closely because it feeds directly into the European Central Bank’s (ECB) interest rate decisions. The ECB’s target is 2% annual inflation over the medium term\, so traders\, bond investors and currency desks use the flash CPI to gauge whether the central bank is likely to hold\, cut or raise borrowing costs at its next meeting. \nWhen is the January 2027 Flash CPI released?\nThe release is expected on Tuesday\, February 2\, 2027 at 11:00 am Central European Time (5:00 am ET\, 10:00 am London time). Eurostat publishes the figures on its euro indicators release calendar page. The exact date has not yet been confirmed by Eurostat at the time of writing: the flash CPI is typically released on the final working day of the reference month or the first working day of the following month\, so this date and time should be treated as indicative until Eurostat’s official calendar confirms it. \nWhat is the consensus forecast?\nA consensus forecast for the January 2027 flash reading has not yet been published. Economist polls for this release\, typically compiled by Reuters or Bloomberg\, are usually circulated only a few days before the print\, so no figure is available this far in advance. \nThe most recently confirmed flash estimate available at the time of writing was for June 2026\, when Eurostat reported euro area annual inflation at 2.8%\, according to the Eurostat euro indicators release. Readers should check the official Eurostat release calendar closer to February 2027 for the latest prior figure and any published consensus. \n\n\n\nMeasure\nPrior (most recent confirmed)\nConsensus\n\n\n\n\nHeadline annual HICP\n2.8% (June 2026 flash)\nNot yet published\n\n\nCore HICP (ex-energy\, food\, alcohol\, tobacco)\nNot confirmed at time of writing\nNot yet published\n\n\n\nWhat the result could mean\n\n\n\nScenario\nLikely market read\nWhat it means in plain English\n\n\n\n\nAbove consensus\nInvestors could price in a slower pace of ECB rate cuts\, pushing euro area government bond yields and the euro higher\nPrices rose faster than expected\, which could keep the cost of borrowing higher for longer\n\n\nIn line with consensus\nLimited market reaction\, with the ECB’s existing policy path largely unchanged\nInflation is behaving roughly as expected\, so no immediate change to interest rate plans\n\n\nBelow consensus\nMarkets could bring forward expectations of ECB rate cuts\, weighing on the euro and bond yields\nPrices rose more slowly than expected\, which could eventually feed through to cheaper loans and mortgages\n\n\n\nThese are possibilities\, not predictions. The actual market reaction will depend on the details within the release\, including the split between energy\, food\, services and core goods prices\, and on what the ECB has signalled at its most recent meeting. \nWhy does this release matter right now?\nEuro area inflation has moved in a wide band over the past two years. Eurostat recorded 2.5% in January 2025\, before cooling in parts of 2025 and early 2026\, with the flash estimate falling to 1.7% in January 2026 and 2.0% in December 2025\, according to Eurostat’s February 2026 release. By June 2026\, the flash estimate had moved back up to 2.8%\, a reminder that the path back to the ECB’s 2% target has not been a straight line. \nThe ECB sets its deposit rate with reference to this kind of data\, alongside wage growth\, energy prices and the exchange rate. A string of readings above target tends to keep the central bank cautious about cutting rates further\, while a run of below-target prints strengthens the case for easing. Analysts and traders will compare the January 2027 flash figure against this recent history to judge whether inflation is trending back towards\, above\, or below the ECB’s target. \nWhat It Means for Your Money\nMortgages and loans: if euro area inflation runs hotter than expected\, the ECB is less likely to cut rates soon\, which keeps variable mortgage and business loan costs across the eurozone higher for longer. A cooler reading raises the chance of cheaper borrowing in the months ahead. \nSavings: savers in euro area banks benefit from higher rates while the ECB holds its current policy stance. If inflation falls and rate cuts follow\, savings account and fixed-term deposit returns are likely to decline over time. \nJobs and wages: persistent inflation above target can squeeze real wages if pay rises do not keep pace\, while falling inflation tends to ease pressure on household budgets even without matching pay increases. \nPrices and the cost of living: this release is one of the clearest signals of whether everyday costs\, such as groceries\, energy bills and eating out\, are still rising faster than normal across the euro area. \nInvestments\, pensions and currencies: the euro\, European government bonds and eurozone equities can all move on this data. A stronger than expected reading tends to support the euro against the dollar and pound\, while a weaker reading can push the currency lower and support export-focused shares. UK and US investors with European exposure\, and savers with euro-denominated pensions\, are directly affected by these swings. \nRelated events\n\nPrevious release: Eurozone Flash CPI\, January 2027\, covering December 2026 data\nThe European Central Bank’s next monetary policy decision\, which will weigh this and prior inflation readings\nNational HICP releases from Germany\, France\, Italy and Spain\, which feed into the euro area aggregate\n\nFrequently Asked Questions\nWhat time is the Eurozone Flash CPI released?\nThe release is expected at 5:00 am ET\, which is 10:00 am London time and 11:00 am Central European Time\, though Eurostat has not yet confirmed the exact date for the January 2027 data. \nHow do I read the flash CPI figure?\nThe headline number is the annual percentage change in prices compared with the same month a year earlier. A rising figure means prices are increasing faster than before\, and a falling figure means price growth is slowing\, not that prices are dropping overall. \nHow does this data affect ECB interest rates?\nThe ECB uses euro area inflation data\, alongside other indicators\, to decide whether to hold\, cut or raise its deposit rate. Inflation running above its 2% target for a sustained period tends to argue against rate cuts\, while inflation below target strengthens the case for easing. \nWhere can I find the official release?\nEurostat publishes the figures on its euro indicators release calendar\, with the full statistical release available on the same page. \nWhen is the next Eurozone Flash CPI released?\nThe following flash estimate\, covering February 2027 data\, is typically published around the end of February or the start of March 2027\, following Eurostat’s usual monthly schedule. \n← Previous Eurozone Flash CPI
URL:https://www.financecalendar.com/event/eurozone-flash-cpi-february-2027/
CATEGORIES:Economic Indicators
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20270202T050000
DTEND;TZID=America/New_York:20270202T060000
DTSTAMP:20261020T010944Z
CREATED:20261020T010944Z
LAST-MODIFIED:20261020T010944Z
UID:3042-1801544400-1801548000@www.financecalendar.com
SUMMARY:Eurozone Unemployment February 2027
DESCRIPTION:Next Eurozone Unemployment: Tuesday\, February 2\, 2027 at 11:00 am CET (5:00 am ET\, 10:00 am London). \nDate to be confirmed by the publisher; this is the scheduled date. \n\nConsensus\nNot yet published\nPrior\nTo be confirmed from January 2027 release\nActual\nPending\n\nFull schedule and background: Eurozone Unemployment. \nUpdated October 19\, 2026 \n\n← Previous Eurozone Unemployment\nEurostat publishes the euro area unemployment rate for December 2026 on February 2\, 2027\, at 11:00 am CET (5:00 am ET\, 10:00 am London time). The release covers the 20 countries that use the euro and is the final labour-market snapshot before the European Central Bank’s early 2027 policy meetings. Full schedule and background: Eurozone Unemployment. \nEurostat has not yet confirmed this exact release date. The agency typically publishes the monthly unemployment figure on the first business day of the month\, roughly five weeks after the reference period ends\, so the date above follows that usual pattern rather than a confirmed Eurostat announcement. \nWhat is the consensus forecast?\nAs this release sits well ahead of the current reporting calendar\, a consensus forecast has not yet been published by Reuters\, Bloomberg or other polling services. These polls are typically compiled only in the days immediately before the release. The table below will be updated once economists’ estimates become available. \n\n\n\nMeasure\nPrior\nConsensus\n\n\n\n\nEuro area unemployment rate\nTo be confirmed from the January 2027 release\nNot yet published\n\n\nYouth unemployment rate (under 25)\nTo be confirmed from the January 2027 release\nNot yet published\n\n\n\nThe euro area jobless rate has generally held near historically low levels in recent years\, according to Eurostat’s release calendar\, though the precise prior reading for this release will depend on the January 2027 figure published a month earlier. See the January 2027 Eurozone unemployment report for the most recent confirmed number once it is out. \nWhat the result could mean\n\n\n\nScenario\nLikely market read\nPlain-English meaning\n\n\n\n\nAbove consensus (higher unemployment)\nEuro may soften; bond yields could ease on growth concerns\nMore people out of work than expected\, a sign the labour market is cooling faster than forecast\n\n\nIn line with consensus\nLimited market reaction; existing ECB rate expectations largely unchanged\nThe labour market is behaving broadly as economists predicted\n\n\nBelow consensus (lower unemployment)\nEuro may firm; some repricing of ECB rate-cut expectations\nFewer people out of work than expected\, which can keep wage pressure and inflation concerns alive\n\n\n\nWhy it matters this week\nThe unemployment rate is one of several labour indicators the European Central Bank weighs when setting interest rates\, alongside wage growth and vacancy data. A tight labour market can keep wage growth elevated\, which the ECB watches closely because it feeds through into services inflation. A weakening labour market\, by contrast\, often strengthens the case for interest rate cuts. \nInvestors outside the eurozone also track this release. A softer than expected reading can pressure the euro against the dollar and the pound\, with knock-on effects for UK and US exporters who sell into European markets\, while a resilient labour market tends to support the single currency and euro area government bond yields. \nWhat It Means for Your Money\nIf you hold savings or investments in euros\, a surprise in this report can move the euro’s exchange rate against the pound or dollar\, which affects anyone converting currency for travel\, property purchases or cross-border business. A weaker euro makes European holidays or imports cheaper for UK and US shoppers\, while a stronger euro has the opposite effect. \nFor mortgage holders and savers in the eurozone\, this data feeds into the ECB’s interest rate decisions. A rising unemployment rate tends to support the case for lower rates\, which could eventually mean cheaper mortgage borrowing but also lower returns on savings accounts. The reverse applies if unemployment stays low and wage pressures persist. \nPension funds and investors with exposure to European equities or bonds may also see short-term price moves around the release\, though a single monthly labour report rarely changes long-term investment strategy on its own. \nFrequently Asked Questions\nWhat time is the Eurozone unemployment report released?\nEurostat is expected to publish the figures at 11:00 am CET\, which is 5:00 am ET and 10:00 am London time\, though this date has not been formally confirmed. \nWhat counts as a significant surprise in this data?\nA move of 0.2 percentage points or more away from the prevailing trend is generally considered notable for a figure that typically changes gradually month to month. \nWhen is the next Eurozone unemployment report?\nEurostat publishes this series monthly\, so the following release covering the next reference month follows roughly a month later\, typically on the first business day of the month. \n← Previous Eurozone Unemployment
URL:https://www.financecalendar.com/event/eurozone-unemployment-february-2027/
CATEGORIES:Economic Indicators
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20270202T070000
DTEND;TZID=America/New_York:20270202T080000
DTSTAMP:20261019T233328Z
CREATED:20261019T233328Z
LAST-MODIFIED:20261019T233328Z
UID:3014-1801551600-1801555200@www.financecalendar.com
SUMMARY:Eli Lilly (LLY) Earnings Q1 2027
DESCRIPTION:Next LLY Quarterly Earnings: Tuesday\, February 2\, 2027 at 7:00 am ET (12:00 pm London). \nDate to be confirmed by the publisher; this is the scheduled date. \n\nConsensus\nNot yet published\nPrior\nEPS $7.02 vs $5.69 consensus\, revenue $17.60bn (Q3 2025)\nActual\nPending\n\nUpdated October 19\, 2026 \n\nEli Lilly and Company (NYSE: LLY) is expected to report its first-quarter 2027 financial results on Tuesday\, February 2\, 2027 at 7:00am ET (12:00pm London). The Indianapolis-based pharmaceutical group\, one of the world’s largest drugmakers by market value\, typically follows its earnings release with a conference call for analysts and investors. Markets watch this release closely because Eli Lilly’s weight-loss and diabetes drugs\, Zepbound and Mounjaro\, have become major drivers of both the company’s revenue and sentiment across the broader healthcare sector. Full schedule and background: Eli Lilly earnings calendar. \nBecause Eli Lilly has not yet confirmed its exact Q1 2027 reporting date at the time of writing\, this page uses an estimated date based on the company’s established pattern. Eli Lilly has historically reported fourth-quarter and full-year results in early February\, so a date near the start of the month is the reasonable working assumption rather than a confirmed fact. \nWhat is the Eli Lilly Q1 2027 earnings release?\nThis is Eli Lilly’s scheduled quarterly disclosure of financial performance\, covering revenue\, earnings per share (EPS\, the portion of profit allocated to each outstanding share)\, and guidance for the year ahead. The report is prepared under US securities law requirements and released via a press statement published on the company’s investor relations site\, followed by a live call where chief executive David Ricks and chief financial officer Lucas Montarce typically take questions from Wall Street analysts. Participants include sell-side analysts from major banks\, institutional investors\, and financial journalists who relay headline numbers to markets within seconds of release. \nEli Lilly’s quarterly results are watched well beyond the United States. The company’s drugs are sold and reimbursed across European health systems\, including the NHS in the United Kingdom\, and its manufacturing and supply decisions affect production sites in Ireland and continental Europe. Strong or weak results can move pharmaceutical shares in London\, Frankfurt and other European markets through sector-wide sentiment\, even though Eli Lilly itself is a US-listed company. \nWhen is the Eli Lilly earnings call and how to follow it\nThe results are expected to be released before the US market opens\, at 7:00am ET\, which is 12:00pm in London and early evening in parts of Asia. A conference call for investors and analysts usually follows shortly after the market open\, typically around 9:00am ET or 2:00pm London time\, though the exact call time is confirmed closer to the date. The release\, an accompanying slide presentation and a live audio webcast are normally made available on Eli Lilly’s investor relations website. Retail investors without access to institutional terminals can usually follow the webcast directly and read the transcript afterwards. \nWhat to expect\nAs of publication\, a consensus forecast for Eli Lilly’s Q1 2027 earnings per share and revenue has not yet been published. Analyst estimates typically firm up in the weeks immediately before the release\, once banks update their models following any pre-announcements\, conference presentations or regulatory news. When a consensus figure becomes available\, it is usually compiled from a poll of sell-side analysts by data providers such as LSEG or FactSet. \nAnalysts are likely to focus closely on sales volumes and pricing for Zepbound (approved for weight management) and Mounjaro (approved for type 2 diabetes)\, since these two drugs have become the single biggest swing factor in Eli Lilly’s results. Other areas of focus typically include manufacturing capacity updates\, given persistent supply constraints on incretin-class drugs\, oncology and immunology pipeline progress\, and any changes to full-year guidance. Currency movements\, particularly a stronger dollar against the euro and pound\, can also affect reported international revenue even when underlying demand is unchanged. \nThe table below shows Eli Lilly’s most recently reported quarterly results\, sourced from the company’s investor relations disclosures\, to provide context ahead of the Q1 2027 release. \n\n\n\nQuarter\nRevenue\nEPS\nvs estimate\n\n\n\n\nQ3 2025\n$17.60 billion\n$7.02\nBeat consensus of $5.69\n\n\n\nOnly the most recently confirmed quarter is included here because earlier figures were not independently verifiable against the company’s own disclosures at the time of writing. Readers wanting the fuller run of historical results should consult Eli Lilly’s investor relations site directly. \nWhat the outcome could mean\n\n\n\nScenario\nLikely market read\nPlain-English meaning\n\n\n\n\nBeat on EPS and revenue\, guidance raised\nShares likely to rise\, pharmaceutical sector sentiment may improve\nDemand for Zepbound and Mounjaro continues to exceed expectations\, and the company is managing supply well enough to convert that demand into sales\n\n\nIn line with expectations\nLimited share price reaction\, attention shifts to forward guidance and pipeline commentary\nThe quarter unfolded roughly as analysts anticipated\, with no major surprises on volumes\, pricing or costs\n\n\nMiss on EPS or revenue\, or guidance cut\nShares likely to fall\, possible knock-on pressure on other weight-loss drug makers\nEither supply constraints\, pricing pressure or slower-than-expected uptake of key drugs is weighing on results\n\n\n\nWhat It Means for Your Money\nEli Lilly is a large constituent of major US stock indices\, so its share price movements feed through to index funds and exchange-traded funds that many pension schemes and workplace savings plans hold\, even for investors who have never bought the stock directly. A big swing in Eli Lilly’s share price\, in either direction\, can therefore have a small but measurable effect on diversified pension pots and index-tracking investment funds in the UK\, Europe and elsewhere. \nThe results can also move the wider healthcare and pharmaceutical sector\, since Eli Lilly’s performance in weight-loss drugs is often treated as a bellwether for rivals such as Novo Nordisk. For savers and investors holding healthcare sector funds\, a strong Eli Lilly report can lift sentiment across the sector\, while a weak one can weigh on it. For everyday consumers\, especially in the US and increasingly in Europe\, commentary on manufacturing capacity and pricing can hint at whether supply shortages or costs for drugs like Zepbound and Mounjaro are likely to ease or persist. There is no direct link between this earnings report and mortgage rates\, currency markets or broader interest rate policy\, so its effects on your money are mostly indirect\, running through pension and investment exposure rather than everyday borrowing costs. \nRelated events\n\nEli Lilly’s full-year 2026 results\, typically reported alongside or just before the Q1 2027 release\nNovo Nordisk quarterly earnings\, a key comparison point in the weight-loss drug market\nUS Consumer Price Index (CPI) release\, which can influence broader market sentiment around the same period\n\nFrequently Asked Questions\nWhat time does Eli Lilly report Q1 2027 earnings?\nThe release is expected at 7:00am ET\, which is 12:00pm in London\, though the date has not been formally confirmed by the company. \nIs the February 2\, 2027 date confirmed?\nNo. It is an estimate based on Eli Lilly’s usual pattern of reporting full-year and fourth-quarter results in early February\, and the exact date will be confirmed closer to the time. \nWhat was Eli Lilly’s most recent reported performance?\nIn its most recently confirmed quarter\, Q3 2025\, Eli Lilly reported EPS of $7.02 against a consensus estimate of $5.69\, on revenue of $17.60 billion. \nWhere can I watch the earnings call live?\nEli Lilly typically streams its earnings call live via a webcast on its investor relations website\, with a transcript posted shortly afterwards. \nWhy does Eli Lilly’s earnings report matter outside the US?\nIts weight-loss and diabetes drugs are sold and reimbursed across European health systems\, and its results often set the tone for pharmaceutical sector sentiment in London and other European markets.
URL:https://www.financecalendar.com/event/eli-lilly-lly-earnings-q1-2027/
CATEGORIES:Earnings Season
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20270202T160500
DTEND;TZID=America/New_York:20270202T170500
DTSTAMP:20261019T210017Z
CREATED:20261019T210017Z
LAST-MODIFIED:20261019T210017Z
UID:2956-1801584300-1801587900@www.financecalendar.com
SUMMARY:Alphabet (GOOGL) Earnings Q1 2027
DESCRIPTION:Next GOOGL Quarterly Earnings: Tuesday\, February 2\, 2027 at 4:05 pm ET (9:05 pm London). \nDate to be confirmed by the publisher; this is the scheduled date. \n\nConsensus\nNot yet published\nPrior\n$119.8 billion revenue\, EPS $9.11 (Q2 2026)\nActual\nPending\n\nUpdated October 19\, 2026 \n\n← Previous GOOGL Quarterly Earnings\nAlphabet Inc. (NASDAQ: GOOGL\, GOOG)\, the parent company of Google\, is expected to report its first-quarter 2027 earnings on Tuesday\, February 2\, 2027 at 4:05 pm ET (9:05 pm London)\, after the US stock market closes. The results will be published by Alphabet’s investor relations team and followed by a conference call with chief executive Sundar Pichai and chief financial officer Anat Ashkenazi. As one of the largest companies in the world by market value\, Alphabet’s numbers move not just its own share price but broader technology indices tracked by pension funds and index trackers worldwide. Full schedule and background: GOOGL quarterly earnings. \nWhat is the Alphabet Q1 2027 earnings report?\nAlphabet reports its financial results four times a year\, covering the three months to March 31 for this release. The report breaks down revenue and profit across Google Search\, YouTube\, Google Network advertising\, Google Cloud\, and “Other Bets” (early-stage ventures such as Waymo\, its self-driving car unit). Analysts\, journalists and large investors dial into the earnings call to question management on advertising demand\, artificial intelligence spending\, and the pace of growth at Google Cloud\, which has become a key profit driver alongside search advertising. \nThe release matters beyond Alphabet shareholders. Google’s advertising business is a bellwether for global marketing budgets\, so a slowdown can signal weaker spending by companies in the UK\, Europe and Asia as well as the US. Google Cloud’s results are also watched as a proxy for corporate demand for artificial intelligence infrastructure. \nWhen is the Alphabet Q1 2027 report and how to follow it\nThe date above\, February 2\, 2027\, is the publisher’s usual pattern for Alphabet’s first-quarter release and has not yet been formally confirmed by the company. Alphabet typically reports in late January or early February for its first quarter\, but it has not published an official date for this specific release at the time of writing. Investors should check Alphabet’s investor relations site closer to the date for the confirmed schedule. \nThe results are usually released as a press statement shortly after 4:00 pm ET\, with a shareholder letter or slide deck posted at the same time. The earnings call\, where executives take analyst questions\, typically begins around 4:30 pm ET (9:30 pm London) and is streamed live on Alphabet’s investor relations website\, with no subscription required. \nWhat to expect\nA consensus forecast for Alphabet’s Q1 2027 revenue and earnings per share has not yet been published\, as analyst estimates for quarters this far ahead are typically only compiled closer to the reporting date. Once available\, consensus figures from data providers such as LSEG or FactSet will be added here. \nBased on recent trends\, analysts are likely to focus on three areas: the growth rate of Google Cloud revenue and whether it remains profitable\, the scale of capital spending on artificial intelligence data centres and chips\, and advertising growth across Search and YouTube. Any commentary on competition from other AI-powered search tools will also be scrutinised\, as will Alphabet’s guidance on future capital expenditure. \n\n\n\nQuarter\nRevenue\nEPS\nvs estimate\n\n\n\n\nQ4 2025\nNot yet verified\nNot yet verified\nNot yet verified\n\n\nQ1 2026\n$110 billion (up 22% year-on-year)\nNot yet verified\nNot yet verified\n\n\nQ2 2026\n$119.8 billion (up 24% year-on-year)\n$9.11 (up 294% year-on-year\, boosted by a one-off gain)\nNot yet verified\n\n\nQ3 2026\nScheduled report date October 28\, 2026\, actual results not yet confirmed in public records at time of writing\nNot yet verified\nNot yet verified\n\n\n\nRevenue figures for Q1 and Q2 2026 are taken from Alphabet’s filings with the US Securities and Exchange Commission. Where a figure could not be independently verified it is marked as such rather than estimated. \nWhat the outcome could mean\n\n\n\nScenario\nLikely market read\nPlain-English meaning\n\n\n\n\nBeat (revenue and profit above consensus)\nShares likely rise\, technology indices supported\nAdvertising and cloud demand held up better than analysts expected\, suggesting the broader economy and AI spending remain strong\n\n\nIn line (results close to consensus)\nLimited share price reaction\, focus shifts to guidance\nGrowth is steady but not accelerating\, so investors look to management’s comments about the months ahead for direction\n\n\nMiss (revenue or profit below consensus)\nShares likely fall\, pressure on wider tech sector\nWeaker advertising or cloud sales could signal softer corporate and consumer spending\, a concern echoed in markets from London to Tokyo\n\n\n\nWhat It Means for Your Money\nAlphabet is one of the largest holdings in most global index funds and workplace pensions\, including funds that track the S&P 500 or the MSCI World index. A sharp move in its share price\, up or down\, can shift the value of retirement savings even for people who have never bought a tech stock directly. A strong report tends to lift sentiment across the technology sector\, supporting other companies that supply chips\, cloud infrastructure or software. A weak report can do the opposite\, and because Alphabet’s advertising revenue reflects marketing budgets at companies worldwide\, a slowdown can hint at tighter corporate spending that eventually reaches the labour market. The report has no direct effect on mortgage rates\, savings rates or the pound\, dollar or euro\, but large swings in US technology shares can influence overall stock market sentiment\, which in turn affects the value of pensions and investment accounts holding global equity funds. \nRelated events\n\nAlphabet’s Q3 2026 earnings release\, the previous quarterly report in this series\nEarnings from other large technology companies reporting in the same window\, such as Microsoft\, Amazon and Meta\nUS non-farm payrolls and inflation data released around the same period\, which influence the broader market backdrop for technology shares\n\nFrequently Asked Questions\nWhen exactly will Alphabet report Q1 2027 earnings?\nThe expected date is February 2\, 2027 at 4:05 pm ET (9:05 pm London)\, based on Alphabet’s usual first-quarter reporting pattern\, though the company has not yet confirmed this date. \nWhat is the consensus forecast for Alphabet’s Q1 2027 results?\nA consensus forecast has not yet been published. Analyst estimates for revenue and earnings per share are typically compiled closer to the reporting date. \nWhere can I watch the Alphabet earnings call live?\nThe call is streamed free of charge on Alphabet’s investor relations website\, usually beginning shortly after the results are released. \nDoes Alphabet’s earnings report affect my pension?\nIf your pension or investment fund holds a global index tracker or a US equity fund\, it is likely to include Alphabet shares\, so large price moves following the report can affect the fund’s value. \nHow does Alphabet’s report affect other technology stocks?\nBecause Alphabet is a major advertising and cloud computing company\, its results are often read as a signal for peers\, and sharp moves can spill over into shares of companies like Microsoft\, Amazon and Meta. \n← Previous GOOGL Quarterly Earnings
URL:https://www.financecalendar.com/event/alphabet-googl-earnings-q1-2027/
CATEGORIES:Earnings Season
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20270202T160500
DTEND;TZID=America/New_York:20270202T170500
DTSTAMP:20261019T225036Z
CREATED:20261019T225036Z
LAST-MODIFIED:20261019T225036Z
UID:3006-1801584300-1801587900@www.financecalendar.com
SUMMARY:AbbVie (ABBV) Earnings Q1 2027
DESCRIPTION:Next ABBV Quarterly Earnings: Tuesday\, February 2\, 2027 at 4:05 pm ET (9:05 pm London). \nDate to be confirmed by the publisher; this is the scheduled date. \n\nConsensus\nNot yet published\nPrior\nNot yet published for this period\nActual\nPending\n\nUpdated October 19\, 2026 \n\nAbbVie (NYSE: ABBV) is scheduled to report quarterly earnings on Tuesday\, February 2\, 2027\, with results due after the market closes at 4:05 pm ET (9:05 pm London). The Chicago-based pharmaceutical group\, known for Humira\, Skyrizi\, Rinvoq and its Botox and aesthetics business\, releases results through a press release and an accompanying investor call\, both published via AbbVie’s investor relations site. Full schedule and background: AbbVie earnings dates. \nThe release matters to a wide range of investors because AbbVie is one of the largest components of US healthcare indices and a regular holding in dividend-focused and pension funds across the US\, UK and Europe. Its results also offer a read on prescription drug pricing\, biosimilar competition and the pace of growth in its post-Humira product lineup\, all of which ripple into healthcare stocks and currency markets when guidance moves sharply. \nWhat is AbbVie’s quarterly earnings report?\nAbbVie’s quarterly earnings report is the company’s official disclosure of revenue\, profit and guidance for the period\, filed with the US Securities and Exchange Commission and published as a press release. It is prepared by AbbVie’s finance team and reviewed by independent auditors\, then presented by the chief executive and chief financial officer on a live conference call with Wall Street analysts. The report breaks down sales by drug and therapeutic area\, covering immunology treatments such as Skyrizi and Rinvoq\, the neuroscience portfolio including Vraylar\, oncology drugs\, and the Allergan aesthetics business built around Botox Cosmetic and Juvederm. \nBecause AbbVie no longer has meaningful Humira revenue after losing US patent exclusivity\, each report is also watched for how quickly newer drugs are offsetting that decline\, a trend analysts have tracked closely since biosimilar competition intensified in 2023. \nWhen is the report and how to follow it\nThe company has not yet formally confirmed the exact date for this release at the time of writing. AbbVie\, like most large US pharmaceutical companies\, typically reports its fourth-quarter and full-year results in the first week of February\, so February 2\, 2027 reflects that usual pattern rather than a confirmed company announcement. Investors should check AbbVie’s investor relations page closer to the date for the final confirmed time. \nResults are released after the New York closing bell\, with the press release posted first\, followed roughly 30 minutes later by a live webcast and conference call where management takes analyst questions. The webcast is streamed free on AbbVie’s investor relations site and a replay is usually available within a few hours. London-based investors watching live should note the call typically falls in the evening\, UK time\, given the 5-hour gap to US Eastern time. \nWhat to expect\nA consensus forecast for this specific report has not yet been published\, since detailed analyst estimates are typically compiled closer to the release date as the quarter closes. Historically\, analysts surveyed by Reuters and Bloomberg build their forecasts around growth in Skyrizi and Rinvoq\, margin trends in the aesthetics division\, and the pace of share buybacks and dividend increases\, all factors likely to shape commentary again this time. \nAbbVie’s most recent full-year results\, covering 2025\, showed adjusted diluted earnings per share of $10.00\, a decrease of 1.2 percent versus 2024\, according to the company’s fourth-quarter and full-year 2025 press release. For the first quarter of 2026\, AbbVie reported adjusted diluted earnings per share of $2.65\, an increase of 7.7 percent year on year\, according to the company’s first-quarter 2026 results statement. Heading into the third quarter of 2026\, AbbVie had guided to adjusted diluted earnings per share of between $3.84 and $3.88\, as set out in a subsequent regulatory filing. \nAnalysts typically focus on three things in AbbVie’s reports: the growth rate of Skyrizi and Rinvoq combined\, which have become the company’s main growth engines since Humira’s decline; margin trends in the aesthetics unit\, which is sensitive to discretionary consumer spending in the US and China; and full-year guidance\, since any change to the outlook tends to move the share price more than the headline quarterly numbers themselves. A verified table of the prior four quarters’ revenue and earnings per share against estimates is not included here\, as not all of the relevant figures for the quarters immediately preceding this release had been independently confirmed via AbbVie’s investor relations materials at the time of writing. Readers wanting the full run of historical results can find them directly on AbbVie’s investor relations site. \nWhat the outcome could mean\n\n\n\nScenario\nLikely market read\nPlain-English meaning\n\n\n\n\nBeat on earnings and raised guidance\nShares likely rise\, healthcare sector sentiment improves\nAbbVie’s newer drugs and aesthetics business are growing faster than expected\, easing concerns about life after Humira\n\n\nIn line with prior guidance\nLimited share price reaction\, focus shifts to forward commentary\nThe business is performing broadly as management predicted\, with no major surprises for investors\n\n\nMiss or guidance cut\nShares likely fall\, pressure on wider pharmaceutical and healthcare indices\nGrowth from key drugs or weaker consumer demand for aesthetics procedures is not covering the loss of Humira sales\n\n\n\nWhat It Means for Your Money\nAbbVie is a major constituent of US healthcare exchange-traded funds and a common holding in workplace pensions and index funds\, including many default pension funds held by UK and European savers through global equity trackers. A strong or weak earnings report can therefore move the value of retirement savings even for people who have never bought an individual share. The company is also one of the largest dividend payers in the pharmaceutical sector\, so changes to its payout or buyback plans can affect income-focused funds that many retirees rely on. \nFor consumers\, AbbVie’s results offer an indirect signal about prescription drug costs and demand for cosmetic procedures such as Botox\, both of which are sensitive to household budgets. A weaker aesthetics result can hint at softer discretionary spending more broadly\, something economists sometimes read as an early sign of consumer caution. Currency moves are a secondary factor: AbbVie earns revenue globally\, so a stronger or weaker dollar against the pound and euro can flatter or dent reported growth\, even when underlying drug sales are stable\, which is one reason currency-hedged versions of US healthcare funds exist for international investors. \nRelated events\n\nOther major US pharmaceutical earnings reported around the same week\, including Pfizer and Merck\nUS Food and Drug Administration decisions affecting AbbVie’s pipeline drugs\nBroader US healthcare sector earnings season coverage\n\nFrequently Asked Questions\nWhat time does AbbVie report earnings on February 2\, 2027?\nAbbVie is expected to report after the market closes\, at 4:05 pm ET\, which is 9:05 pm in London\, though the company has not yet formally confirmed the exact time for this release. \nIs the February 2\, 2027 date confirmed by AbbVie?\nNo\, the date is an estimate based on AbbVie’s usual pattern of reporting full-year and fourth-quarter results in the first week of February. The confirmed date is typically announced a few weeks in advance on the company’s investor relations site. \nWhere can I watch AbbVie’s earnings call live?\nThe call is streamed free via a webcast link on AbbVie’s investor relations website\, with a replay usually posted within a few hours of the live event. \nWhat is the consensus forecast for this report?\nA consensus forecast had not yet been published at the time of writing\, as analyst estimates for this specific quarter are typically compiled closer to the release date. \nWhy do AbbVie’s results affect my pension even if I do not own the shares directly?\nMany pension funds and index trackers hold AbbVie as part of broad US healthcare or S&P 500 exposure\, so a significant move in its share price after earnings can have a small but real effect on the value of those funds.
URL:https://www.financecalendar.com/event/abbvie-abbv-earnings-q1-2027/
CATEGORIES:Earnings Season
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20270202T160500
DTEND;TZID=America/New_York:20270202T170500
DTSTAMP:20261019T225139Z
CREATED:20261019T225139Z
LAST-MODIFIED:20261019T225139Z
UID:3008-1801584300-1801587900@www.financecalendar.com
SUMMARY:Qualcomm (QCOM) Earnings Q1 2027
DESCRIPTION:Next QCOM Quarterly Earnings: Tuesday\, February 2\, 2027 at 4:05 pm ET (9:05 pm London). \nDate to be confirmed by the publisher; this is the scheduled date. \n\nConsensus\nNot yet published\nPrior\nQ4 FY2025: Revenue $11.27bn\, non-GAAP EPS $3.00 (reported November 5\, 2025)\nActual\nPending\n\nUpdated October 19\, 2026 \n\nQualcomm Incorporated (NASDAQ: QCOM) is expected to report its fiscal first-quarter 2027 results on Tuesday\, February 2\, 2027\, with the figures released after the US market closes at around 4:05 pm ET (9:05 pm London). The company has not yet confirmed this date; it is estimated because Qualcomm has historically reported its fiscal first-quarter results (covering the quarter ending late December) in late January or early February\, followed by a conference call with analysts. Full schedule and background: Qualcomm earnings calendar. The release matters to markets well beyond San Diego\, where Qualcomm is based\, because the company supplies chips that power the majority of the world’s Android smartphones and is expanding into automotive\, PCs and data centre connectivity. Its results are watched closely in Asia\, where its biggest customers and component suppliers are based\, and in Europe\, where automakers increasingly rely on Qualcomm’s Snapdragon Digital Chassis platform. \nWhat is a Qualcomm earnings release?\nQualcomm’s quarterly earnings release is a standard public company disclosure under US Securities and Exchange Commission rules. The company publishes a press release detailing revenue\, profit and segment performance\, followed by a conference call in which chief executive Cristiano Amon and chief financial officer Akash Palkhiwala discuss results and answer questions from Wall Street analysts. The fiscal first quarter covers the three months to late December\, meaning the report due around February 2\, 2027 reflects the crucial year-end holiday shopping period for smartphones\, a core driver of Qualcomm’s largest division\, Qualcomm CDMA Technologies (QCT)\, which designs and sells mobile chips. \nAlongside QCT\, Qualcomm also reports results for Qualcomm Technology Licensing (QTL)\, which earns royalties from patents used in mobile communication standards. Analysts and investors track both divisions separately because QTL carries far higher margins and is less cyclical than chip sales. \nWhen is the report and how to follow it\nThe press release is expected shortly after 4:00 pm ET (9:00 pm London) on February 2\, 2027\, with the earnings conference call typically following around 30 to 45 minutes later. Results and the accompanying investor presentation are published on Qualcomm’s own investor relations site\, and the call is usually streamed live with a replay made available afterwards. As the date has not been formally confirmed by Qualcomm\, readers should check the Qualcomm Investor Relations page closer to the time\, since companies occasionally shift earnings dates by a day or two. \nFor context\, Qualcomm’s fiscal fourth quarter and full-year 2025 results were reported on November 5\, 2025\, with revenue of $11.27 billion and non-GAAP earnings per share of $3.00\, both ahead of analyst expectations\, according to CNBC’s coverage of the release. \nWhat to expect\nA consensus forecast for Qualcomm’s fiscal first-quarter 2027 earnings per share and revenue has not yet been published. Estimates typically firm up in the weeks before the release as analysts update models following Qualcomm’s own guidance from the prior quarter’s call. Investors will be watching several themes: \n\nSmartphone chip demand\, particularly for premium Android handsets\, which has been Qualcomm’s largest and most cyclical revenue source.\nApple exposure\, since Qualcomm has previously flagged declining modem chip revenue from Apple as the iPhone maker develops its own modems in-house.\nAutomotive and Internet of Things (IoT) growth\, areas Qualcomm has highlighted as diversifying its business away from handsets\, including data centre and robotics ambitions.\nForward guidance for the following quarter\, which often moves the share price more than the headline numbers themselves.\n\nA table showing the last four quarters of verified revenue\, earnings per share and consensus comparisons has been omitted from this page because fully verified\, like-for-like figures for the most recent quarters were not available from Qualcomm’s investor relations site at the time of writing. Readers wanting the latest confirmed numbers should consult Qualcomm’s own quarterly earnings releases directly. \nWhat the outcome could mean\n\n\n\nScenario\nLikely market read\nPlain-English meaning\n\n\n\n\nBeat on revenue and EPS\, strong guidance\nShares likely to rise\, seen as a sign of resilient smartphone and automotive demand\nQualcomm sold more chips than expected and expects the trend to continue\n\n\nIn line with expectations\nMuted share reaction\, focus shifts to forward guidance and segment detail\nBusiness performed roughly as analysts predicted\, no major surprise\n\n\nMiss on revenue\, EPS or weak guidance\nShares likely to fall\, scrutiny on handset demand and diversification progress\nChip sales or profit came in lower than hoped\, raising questions about near-term demand\n\n\n\nWhat It Means for Your Money\nQualcomm is a large constituent of major US stock indices\, so its share price movements affect the value of index funds and exchange-traded funds commonly held in workplace pensions and individual savings accounts in the UK\, Europe and Asia\, even for people who have never bought the stock directly. A sharp earnings beat or miss can also move semiconductor peers and suppliers\, given how closely chip companies’ fortunes are linked through the smartphone and automotive supply chain. For consumers\, Qualcomm’s results offer an early signal on smartphone demand and pricing trends\, which can feed into the cost of new handsets. Currency moves in the dollar can also affect Qualcomm’s reported results\, since the bulk of its revenue is generated overseas\, particularly in Asia\, where most of its customers manufacture devices. None of this should be read as investment advice; share price reactions to a single earnings report are often short-lived and can reverse within days. \nRelated events\n\nOther major semiconductor earnings releases in the same reporting season\, including rivals in mobile and automotive chips\nUS nonfarm payrolls and labour market data\, which can influence overall market sentiment around the same period\nFederal Reserve interest rate decisions\, which affect valuations across the technology sector\n\nFrequently Asked Questions\nWhat time does Qualcomm report Q1 2027 earnings?\nThe release is expected around 4:05 pm ET (9:05 pm London) on February 2\, 2027\, though Qualcomm has not formally confirmed the date. \nIs the February 2\, 2027 date confirmed?\nNo. It is an estimate based on Qualcomm’s pattern of reporting fiscal first-quarter results in late January or early February each year. \nWhat was Qualcomm’s prior quarterly result?\nThe most recently confirmed full release was for fiscal fourth quarter 2025\, reported on November 5\, 2025\, with revenue of $11.27 billion and non-GAAP EPS of $3.00\, both ahead of analyst estimates\, according to CNBC. \nWhere can I watch or read the results live?\nQualcomm publishes its press release and hosts a live-streamed conference call on its own investor relations website\, with a replay typically available afterwards. \nWhy does Qualcomm’s earnings report matter outside the US?\nQualcomm’s chips are used in handsets\, cars and connected devices sold worldwide\, so its results offer a read on global technology demand and can move related stocks and currency-linked supply chains in Asia and Europe.
URL:https://www.financecalendar.com/event/qualcomm-qcom-earnings-q1-2027/
CATEGORIES:Earnings Season
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20270202T160500
DTEND;TZID=America/New_York:20270202T170500
DTSTAMP:20261019T232827Z
CREATED:20261019T232827Z
LAST-MODIFIED:20261019T232827Z
UID:3010-1801584300-1801587900@www.financecalendar.com
SUMMARY:Merck (MRK) Earnings Q1 2027
DESCRIPTION:Next MRK Quarterly Earnings: Tuesday\, February 2\, 2027 at 4:05 pm ET (9:05 pm London). \nDate to be confirmed by the publisher; this is the scheduled date. \n\nConsensus\nNot yet published\nPrior\nNon-GAAP EPS -$0.13 (Q2 2026\, miss vs $0.23 est.)\nActual\nPending\n\nUpdated October 19\, 2026 \n\nMerck & Co. (NYSE: MRK)\, known as MSD outside the United States and Canada\, is expected to report its fourth-quarter and full-year 2026 financial results on Tuesday\, February 2\, 2027\, with the release and conference call scheduled for 4:05pm ET (9:05pm London). The date has not yet been confirmed by Merck and is based on the company’s usual pattern of reporting full-year results in the first days of February\, as it did on February 3\, 2026 for the 2025 fiscal year. Investors across the US\, Europe and Asia watch this release closely because Merck is one of the world’s largest pharmaceutical companies\, with its cancer drug Keytruda alone generating tens of billions of dollars a year in sales. Full schedule and background: Merck earnings calendar. \nThe event sits within Merck’s broader quarterly reporting calendar\, which also includes calls on drug approvals\, patent developments and dividend announcements throughout the year. Because the pharmaceutical sector trades on long-term pipeline expectations as much as short-term sales\, a single quarterly report rarely moves Merck’s share price as dramatically as\, say\, a central bank rate decision moves currency markets. Even so\, large misses or beats against Wall Street expectations can shift sentiment across the wider healthcare sector\, given Merck’s size and influence as a bellwether stock. \nWhat is the Merck Q4 2026 earnings release?\nThis is Merck’s quarterly results announcement\, in which the company discloses revenue\, profit (both under standard GAAP accounting rules and an adjusted “non-GAAP” measure that strips out one-off items like acquisition costs)\, and guidance for the coming year. Merck’s chief executive\, Robert M. Davis\, and chief financial officer typically host a call with analysts straight after the figures are published\, taking questions on drug sales\, pipeline progress and cost pressures such as US tariffs. Because Merck sells medicines and vaccines in more than 140 countries\, the results also offer a read on global healthcare demand and currency effects on multinational earnings. Analysts also use the call to probe management on regulatory risk\, including ongoing discussions in the US around drug pricing reform and the impact of tariffs on pharmaceutical supply chains\, both of which have featured prominently in recent Merck results releases. \nWhen is the release and how to follow it\nMerck usually issues its results via press release before the US market opens or\, for recent quarters\, in the early afternoon\, followed by a webcast conference call in the afternoon. For the comparable Q4 2025 report\, the results were published on February 3\, 2026. As this date is an estimate\, readers should check Merck’s investor relations site nearer the time for the confirmed date and webcast link. The call is typically archived on the same page for anyone who misses the live broadcast. \nShareholders and journalists based in Europe should note the late evening London time of 9:05pm\, which means the market reaction is usually first visible in US after-hours trading rather than during European trading hours. Asian markets\, including Tokyo and Hong Kong\, will typically see any reaction unfold during their following trading session. \nWhat to expect\nA consensus forecast for the Q4 2026 report has not yet been published\, as analyst estimates for quarters this far ahead are not yet widely tracked. For context\, analysts surveyed by Yahoo Finance had pencilled in full-year 2026 non-GAAP earnings per share (EPS) of around $2.66 to $2.76\, according to Merck’s own guidance issued in its second-quarter 2026 results. Investors will watch Keytruda sales growth\, progress in Merck’s vaccines business\, and the integration costs from the acquisition of Terns Pharmaceuticals\, which weighed heavily on second-quarter 2026 results. Guidance for 2027\, including any update on patent expiries and pipeline drugs intended to offset Keytruda’s eventual loss of exclusivity\, will also be closely read. \nMerck’s recent quarters have been notably volatile on a reported basis because of large one-off charges\, including costs tied to its acquisition of Terns Pharmaceuticals and earlier licensing payments to Hengrui Pharmaceutical. These items have pushed GAAP and non-GAAP EPS into negative territory in some quarters even as underlying product sales continued to grow\, a distinction investors will want to keep in mind when comparing headline numbers across quarters. \n\n\n\nQuarter\nRevenue\nNon-GAAP EPS\nvs estimate\n\n\n\n\nQ3 2025\n$17.28 billion\n$2.58\nBeat ($2.35 est.)\n\n\nQ4 2025\n$16.40 billion\n$2.04\nBeat ($2.02 est.)\n\n\nQ1 2026\nNot separately confirmed\n-$1.28\nBeat (-$1.48 est.)\n\n\nQ2 2026\n$16.61 billion\n-$0.13\nMiss ($0.23 est.)\n\n\n\nWhat the outcome could mean\n\n\n\nScenario\nLikely market read\nPlain-English meaning\n\n\n\n\nBeat on EPS and revenue\, strong 2027 guidance\nShares likely rise\, reassurance for pharma sector sentiment\nMerck’s drug sales and cost control are stronger than analysts expected\, and the outlook for next year looks healthier\n\n\nIn line with estimates\nLimited share price reaction either way\nResults broadly match what analysts already priced in\, so little changes for investors\n\n\nMiss on EPS or weak 2027 guidance\nShares likely fall\, renewed focus on Keytruda patent cliff\nProfit or sales growth disappoints\, raising concerns about how Merck will replace future lost revenue from its top-selling drug\n\n\n\nWhat It Means for Your Money\nMerck is a large constituent of major US indices\, so it is held\, directly or indirectly\, in many pension funds\, workplace pension schemes and index-tracking investment funds across the UK\, Europe and Asia. A strong or weak result can move the healthcare sector of those funds even if an individual saver has never bought the stock directly. For currency markets\, Merck’s global sales mean its results can offer a small signal on dollar demand relative to the pound and euro\, though this effect is modest compared with central bank decisions. For ordinary consumers\, Merck’s drug pricing strategy and any guidance on US policy toward medicine costs can be an early indicator of trends that eventually affect prescription and insurance costs in the United States\, with less direct impact on UK and European patients who largely rely on national health systems. \nRelated events\n\nMerck’s third-quarter 2026 earnings release\, typically reported in late October\nPfizer and Johnson & Johnson quarterly earnings\, often released in the same reporting window\nUS Food and Drug Administration decisions affecting Merck’s pipeline drugs\n\nFrequently Asked Questions\nWhat time does Merck report its Q4 2026 earnings?\nThe release is expected at 4:05pm ET (9:05pm London) on February 2\, 2027\, though Merck has not yet confirmed the exact date. \nWhat was Merck’s most recent EPS?\nIn its most recently reported quarter\, Merck posted non-GAAP EPS of -$0.13\, missing the analyst estimate of $0.23\, largely due to acquisition-related charges\, according to Merck’s own results announcement. \nIs there a consensus forecast for this report yet?\nNo\, a consensus forecast has not yet been published for the Q4 2026 results\, as estimates this far ahead are not widely tracked by analysts. \nWhy does Merck’s earnings report matter beyond the US?\nMerck sells medicines and vaccines in more than 140 countries\, so its results offer a broader read on global healthcare demand\, drug pricing trends and currency effects that can ripple into pension and index funds held by investors in the UK\, Europe and Asia. \nWhere can I watch the earnings call live?\nMerck typically streams its earnings call via a webcast link posted on its investor relations website\, with a replay available afterwards.
URL:https://www.financecalendar.com/event/merck-mrk-earnings-q1-2027/
CATEGORIES:Earnings Season
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20270202T160500
DTEND;TZID=America/New_York:20270202T170500
DTSTAMP:20261019T233106Z
CREATED:20261019T233106Z
LAST-MODIFIED:20261019T233106Z
UID:3012-1801584300-1801587900@www.financecalendar.com
SUMMARY:Uber (UBER) Earnings Q1 2027
DESCRIPTION:Next UBER Quarterly Earnings: Tuesday\, February 2\, 2027 at 4:05 pm ET (9:05 pm London). \nDate to be confirmed by the publisher; this is the scheduled date. \n\nConsensus\nUber Q3 2025 EPS was $3.11\, beating estimates\, with revenue of $13.5 billion\nPrior\nEPS $3.11\, revenue $13.5 billion (Q3 2025\, beat estimates)\nActual\nPending\n\nUpdated October 19\, 2026 \n\nUber Technologies (NYSE: UBER) is scheduled to report fourth-quarter and full-year 2026 results\, covering the period widely referred to as Q1 2027 in the earnings calendar cycle\, on Tuesday\, February 2\, 2027\, at 4:05 pm ET (9:05 pm London). The release and accompanying investor call are published through Uber’s own investor relations channel rather than a third-party exchange. For the full schedule of Uber’s quarterly reporting dates and background on the series\, see Uber earnings calendar. \nBecause Uber has not yet confirmed the exact date for this report\, the date above is an estimate based on the company’s usual pattern of reporting roughly five to six weeks after the end of a calendar quarter. Investors\, drivers\, and anyone holding Uber shares through a pension fund or index tracker should treat the date as provisional until Uber issues a formal notice\, which typically happens two to three weeks in advance. \nWhat is Uber’s quarterly earnings report?\nUber’s quarterly earnings report is the company’s official disclosure of its financial performance\, filed with the US Securities and Exchange Commission and published as a press release on its investor relations site. It covers revenue\, profit or loss\, gross bookings (the total value of trips and deliveries booked on the platform before Uber takes its cut)\, adjusted EBITDA (earnings before interest\, tax\, depreciation and amortisation\, a measure of underlying operating profitability)\, and cash flow. Management\, led by chief executive Dara Khosrowshahi and chief financial officer Prashanth Mahendra-Rajah\, hosts a live conference call shortly after the release to answer questions from analysts covering the stock. \nThe report matters beyond Uber shareholders because the company is viewed as a bellwether for the broader gig economy and on-demand consumer spending. Its mobility and delivery segments offer a read on discretionary spending trends in the United States\, Europe\, Latin America and parts of Asia\, making the release relevant to anyone tracking global consumer health\, not just US-focused investors. \nWhen is Uber’s Q1 2027 earnings report and how to follow it\nThe release is expected after the US stock market closes\, at 4:05 pm ET (9:05 pm in London)\, with the earnings call typically starting around 8:00 am Pacific Time\, roughly 30 minutes after the numbers are published. The results and a live audio webcast of the call are available through Uber’s investor relations website\, where a replay is usually posted within a few hours. Financial news wires and most major brokerage platforms carry the headline figures within minutes of release\, and a written transcript is generally available the following day through services that cover earnings calls. \nAs this date is estimated rather than confirmed\, readers should check Uber’s investor relations page in the weeks beforehand\, since the company sometimes shifts its reporting date by a few days from the pattern seen in prior quarters. \nWhat to expect\nA consensus forecast for this specific quarter has not yet been published\, as analyst estimates are typically only compiled in the two to three weeks before a results date. The most useful reference point is Uber’s most recent reported quarter\, Q3 2025\, when the company posted earnings per share (EPS) of $3.11 and revenue of $13.5 billion\, both ahead of analyst estimates\, according to Uber’s own SEC filing and corroborated by GuruFocus’s earnings summary. In that quarter trips grew 22% year-on-year and gross bookings rose 21%\, with adjusted EBITDA of $2.3 billion\, up 33% year-on-year. \nAnalysts following Uber tend to focus on a handful of recurring themes: growth in gross bookings across mobility (ride-hailing) and delivery\, the pace of expansion in newer categories such as grocery and advertising\, progress on autonomous vehicle partnerships\, margin trends in adjusted EBITDA\, and free cash flow generation. Guidance for the following quarter\, usually given alongside the results\, is often a bigger share-price driver than the headline numbers themselves\, since it shapes expectations for the rest of the year. \n\n\n\nQuarter\nRevenue\nEPS\nvs estimate\n\n\n\n\nQ3 2025\n$13.5 billion\n$3.11\nBeat\n\n\nQ2 2025\nNot independently verified for this page\nNot independently verified for this page\n–\n\n\nQ1 2025\nNot independently verified for this page\nNot independently verified for this page\n–\n\n\nQ4 2024\nNot independently verified for this page\nNot independently verified for this page\n–\n\n\n\nWhat the outcome could mean\n\n\n\nScenario\nLikely market read\nPlain-English meaning\n\n\n\n\nBeat on EPS and revenue\, strong guidance\nShares likely rise\, analysts may raise price targets\nUber’s core ride-hailing and delivery business is growing faster or more profitably than expected\n\n\nIn line with prior trends\, cautious guidance\nMuted or mixed share reaction\nGrowth is steady but not accelerating\, management is managing expectations for the next quarter\n\n\nMiss on bookings growth or margins\nShares likely fall\, questions raised about competitive pressure\nCosts\, competition from rivals\, or weaker consumer demand are squeezing profitability\n\n\n\nWhat It Means for Your Money\nUber is a large constituent of several widely held US and global index funds\, so most people with a workplace pension or a broad index tracker already have some indirect exposure to its share price\, even if they have never bought the stock directly. A sharp move in Uber’s share price on results day will have a small but real effect on the value of diversified funds that include US technology and consumer stocks. \nFor everyday consumers\, Uber’s results can hint at pricing trends for ride-hailing and food delivery: stronger-than-expected profitability sometimes comes alongside higher prices or reduced driver incentives\, while a weaker quarter can lead to renewed promotions to win back demand. For gig workers who drive or deliver for Uber\, the company’s commentary on driver supply\, incentive spending and regulatory costs can be a signal of how pay and bonus structures might shift in coming months. The report has limited direct effect on currencies\, but a large swing in a major US stock can feed into broader risk sentiment that touches the dollar\, the pound and the euro on the day. \nRelated events\n\nUber’s prior quarterly earnings release (Q4 2026 results\, reported ahead of this one)\nOther major ride-hailing and delivery company earnings\, such as Lyft and DoorDash\, often reported in the same window\nUS monthly jobs report\, which offers a broader read on consumer spending power around the same time\n\nFrequently Asked Questions\nWhat time does Uber report Q1 2027 earnings?\nThe report is expected at 4:05 pm ET (9:05 pm London) on February 2\, 2027\, though this date is an estimate pending official confirmation from Uber. \nWhere can I watch or listen to Uber’s earnings call?\nThe press release and a live audio webcast of the call are published on Uber’s investor relations website\, with a replay typically posted afterwards. \nWhat was Uber’s most recent reported result?\nIn its most recently reported quarter\, Q3 2025\, Uber posted EPS of $3.11 and revenue of $13.5 billion\, both ahead of analyst estimates. \nIs there a consensus forecast for this report yet?\nNo\, a consensus forecast has not yet been published for this specific quarter. Estimates are usually compiled by analysts in the final few weeks before the release. \nWhy does Uber’s earnings date sometimes change?\nUber\, like most companies\, finalises its reporting calendar only a few weeks ahead of the actual date\, so the schedule can shift slightly from the pattern seen in previous quarters.
URL:https://www.financecalendar.com/event/uber-uber-earnings-q1-2027/
CATEGORIES:Earnings Season
END:VEVENT
END:VCALENDAR